**************************************************************

PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives,reported that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc. investment opportunity to institutional investors.

Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.

The recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC. (”XGen”), a Nevis Island limited liability company. For additional details about the joint venture agreement, please refer to the August 17, 2010 press release.

“Proteonomix has made great strides recently,” stated Mr. Cohen, “and we have been contacted by several European entities that have requested additional information about our proprietary stem cell activities. In recognition of the interest in Europe and the potential for additional joint venture agreements in various European countries, we recognize that it is propitious to meet with a number of the European institutional investors both to educate them on the intrinsic value of Proteonomix shares and garner interest in strategic relationships.”

StemCells, Inc. (Nasdaq:STEM) reports that its technology was recently used by independent researchers to achieve the first genetically engineered rat derived from rat embryonic stem (ES) cells. This breakthrough, published this month in the international peer-reviewed journal Nature, opens the door to the types of genetic manipulations previously only possible in mice, and paves the way for modeling a broader range of human diseases with the rat. Both mice and rats are used as animal models of human disease; however certain aspects of the rat’s physiology, behavior, and metabolism are closer to the human, making rats the preferred species for drug development and studying human disease. The creation of this first rat model using rat ES cells validates intellectual property owned by StemCells, which includes the rights to patents covering both rat ES and rat induced pluripotent stem (iPS) cells as well as genetically engineered rats derived from these cells.

StemCells’ broad rat pluripotent stem cell intellectual property portfolio is based upon groundbreaking research led by prominent academic researchers at the University of Edinburgh, including Dr. Qi-Long Ying who was the first to succeed in deriving and culturing the true germline competent rat ES cells required for precise genetic engineering. In this newly published study, Dr. Qi-Long Ying and his colleagues at the Eli and Edythe Broad Center for Regenerative Medicine and Stem Cell Research at the University of Southern California demonstrated for the first time the creation of genetically modified rats using rat ES cells that have been gene targeted via homologous recombination, a method which involves adding DNA sequences to the cells to delete (’knock-out’), add (’knock-in’) or otherwise modify genes of interest. This latest work resulted in the successful generation of knock-out rats missing the tumor suppressor gene p53 for use in studying cancer, and serves as a proof-of-principle for creating genetically engineered rats using rat ES cells.

Genzyme Corp. (NASDAQ: GENZ) and Isis Pharmaceuticals Inc. report that data from the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) were presented at the European Society of Cardiology’s Congress 2010 in Stockholm, Sweden. The study met its primary endpoint with a 28 percent reduction in LDL-cholesterol, compared with an increase of 5 percent for placebo. The trial also met all of its secondary and tertiary endpoints. Frequently observed adverse events were injection site reactions, flu-like symptoms and elevations in liver transaminases, as seen in other mipomersen studies.

This double-blind, placebo-controlled phase 3 study was designed to test the efficacy and safety of adding mipomersen to stable lipid-lowering therapy. Patients were randomized 2:1 to receive a 200 mg dose of mipomersen or placebo weekly for 26 weeks. The trial included 124 adult heFH patients at 26 sites in the United States and Canada. All of the patients had pre-existing coronary artery disease and LDL-C levels greater than 100 mg/dL, and were taking a maximally tolerated dose of a statin, as well as additional lipid-lowering drugs in most cases. Prior to study enrollment, 78 percent of patients had previously experienced at least one cardiovascular event and 49 percent had more than one previous cardiovascular event.

One of the world’s leading biotechnology companies, Genzyme is dedicated to making a major positive impact on the lives of people with serious diseases. Since 1981, the company has grown from a small start-up to a diversified enterprise with more than 12,000 employees in locations spanning the globe and 2009 revenues of $4.5 billion. In 2010, Genzyme was named to the Fortune 500.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)

**************************************************************

Power3 Medical Products, Inc. (PWRM.OB) is a leading bio-technology company focused on the development of innovative diagnostic tests in the fields of cancer and neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease and amyotrophic lateral sclerosis (commonly known as ALS or Lou Gehrig’s disease). Power3 applies proprietary methodologies to discover and identify protein biomarkers associated with diseases. Through these processes, Power3 has developed a portfolio of products including BC-SeraPro, a proteomic blood serum test for the early detection of breast cancer for which it has completed Phase I clinical trials, and NuroProÂ, a serum test for the detection of neurodegenerative diseases, including Alzheimer’s, Parkinson’s and ALS diseases, currently engaged in Phase II clinical trials.

Power3 Medical Products, Inc. recently reported that, in collaboration with Lourdes R. Bosquez, MD, it has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimers disease patients compared to patients treated with the widely used anti-dementia drugs Aricept, Exelon, and Namenda. These results relate to the genetically distinct groups of Alzheimers disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.

NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.

ARIAD (Nasdaq:ARIA) originates from the Greek myth of Ariadne, a daughter of Minos II, king of Crete. According to the myth, Ariadne fell in love with Theseus and gave him a spool of thread that enabled him to trace his path safely in and out of the labyrinth in which the Minotaur lived.

After slaying the Minotaur, Theseus used the spool of thread to successfully return home. From ARIAD’s perspective, the labyrinth symbolizes the complex system of molecular pathways within the cell, and the spool of thread represents the signaling pathways that are leading ARIAD’s scientists to the discovery of breakthrough cancer therapies.

The focus at ARIAD is to discover and develop new drugs that will dramatically expand and improve current treatment options for patients with cancer. ARIAD’s story starts with their vision, which reflects who they are, where they’re going and what they are trying to do. ARIAD’s mission and values keep them focused on the kind of company—and people—they want to be.

ARIAD’s vision is to transform the lives of cancer patients with breakthrough medicines.

ARIAD’s mission is to discover, develop and commercialize small-molecule drugs to treat cancer in patients with the greatest unmet medical need—aggressive cancers where current therapies are inadequate. ARIAD is committed to the highest standards of integrity and stewardship in service to patients, the medical community, employees and shareholders.

BSD Medical Corporation (NASDAQ:BSDM) has entered into a securities purchase agreement with two existing institutional investors for the sale of 1,225,000 shares of its common stock in a registered direct offering at $2.25 per share. In addition, warrants to purchase 918,750 shares of common stock in the aggregate will be issued to the investors. The warrants are exercisable beginning six months and one day after closing, expire 5 years after becoming exercisable and have an exercise price of $3.27 per share. Gross proceeds of the offering, before deducting placement agent fees and other estimated offering expenses payable by BSD Medical Corporation, are expected to be approximately $2.75 million. These securities are being offered through a prospectus supplement pursuant to the Company’s effective shelf registration statement and base prospectus contained therein.

The net proceeds from this offering will be used for continuing product development, sales and marketing, and general corporate purposes. In the securities purchase agreement BSDM has entered into with the purchasers in this offering, BSDM has agreed not to use the proceeds of this offering to satisfy any existing debt (other than ordinary course trade payables), to redeem any of outstanding securities or to settle any outstanding litigation.

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radio frequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system, which the Company will introduce to the market this year, has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has extensive intellectual property, multiple products in the market and well established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals in the United States, Europe and China.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)

**************************************************************

Power3 Medical Products, Inc. (OTCBB: PWRM), in collaboration with Lourdes R. Bosquez, MD, has unexpectedly discovered new and unprecedented findings regarding clinically important differences in the response of the NuroPro protein biomarkers in the blood of untreated Alzheimer’s disease patients compared to patients treated with the widely used anti-dementia drugs Aricept (Donepezil HCl, Pfizer – NYSE: PFE), Exelon (Rivastigmine, Novartis – NYSE: NVS), and Namenda (Memantine HCl, Forest Laboratories – NYSE: FRX). These results relate to the genetically distinct groups of Alzheimer’s disease patients, i.e., those individuals who possess the Alzheimer’s high-risk gene for Apolipoprotein E4 and those who do not possess the gene.

NuroPro was originally indicated for diagnostics to determine whether or not a patient had Alzheimer’s disease. With these results, NuroPro now extends into the pharmaceutical arena due to its ability to predict and monitor the response to drug treatment, including the underlying disease process and the insidious progression of irreversible neurological damage, even in the face of temporary improvements in cognition and other symptoms.

Power3 has filed for patent protection for these findings and will be publishing these seminal results in the near future in one of the world’s most prestigious peer-reviewed scientific journals. Power3 also plans to demonstrate the clinical application and benefits of its NuroPro diagnostic tests to healthcare providers located throughout the world. Power3 believes that this will assist the company greatly in an effort to generate sales of its NuroPro diagnostic tests. Power3 is currently working on a joint distribution effort with a number of potential business partners, such as the companies mentioned above, for the sale of its NuroPro diagnostic tests and the development of new drugs.

“This new and amazing discovery will help clarify some of the clinical observations and overcome difficulties that we have had as physicians, not only by helping us choose more appropriate treatment and better predict response, but also by helping us find more permanent treatments for the dementias,” said Dr. Bosquez.

Ira L. Goldknopf, Ph.D., President and Chief Scientific Officer of Power3, stated, “This innovation will provide physicians with an invaluable perspective to use in the treatment of their patients and will have profound implications for the diagnosis and treatment of Alzheimer’s disease, and for other diseases as well.”

PROTEONOMIX, INC. (PROT.OB), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, has formed a new subsidiary called X Gen Medical LLC, a Nevis Virgin Island entity. X Gen Medical has been established with the intention of conducting business in the global medical marketplace. Proteonomix plans on utilizing X Gen Medical to serve as a platform for joint ventures with medical facilities worldwide. It is anticipated that new relationships formed with X Gen Medical will create medical facilities capable of not just attracting treatments locally, but also acting as hubs for medical tourism. Medical tourism is constantly on the rise and anticipated to continue to grow substantially due to current high costs of health care for certain procedures and improvements in both technology and standards of care in many countries.

Mr. Michael Cohen, Chairman and CEO of Proteonomix, stated, “We have been in negotiations with several groups, specifically in the Middle East and Europe, to establish Proteonomix Regenerative Translational Medicine Institute (”PRTMI”) medical facilities in those regions. The negotiations have reached the level whereby the establishment of a separate subsidiary, X Gen Medical LLC., was essential in order to allow Proteonomix to properly enter these global markets with the intention of soliciting business through our proprietary PRTMI model. We anticipate closing on some of these negotiations in the near future, which we anticipate will include the necessary funding required to firmly establish X Gen Medical as a PRTMI provider.”

Proteoderm, Inc. a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD). StromaCel, Inc. is pursuing the licensing of other technologies for therapeutic use. National Stem Cell, Inc. is Proteonomix’s operating subsidiary. The Sperm Bank of New York, Inc. is a fully operational tissue bank. Proteonomix Regenerative Translational Medicine Institute, Inc. (”PRTMI”) intends to focus on the translation of promising research in stem cell biology and cellular therapy to clinical applications of regenerative medicine. Proteonomix intends to create and dedicate a subsidiary to each of its technologies.

OXiGENE, Inc., (Nasdaq:OXGN), a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the quarter and six months ended June 30, 2010, and presented an update on recent clinical and corporate progress.

In July, the Company presented an update on its ZYBRESTAT ophthalmology program, including preclinical data showing that the Company’s topical formulation achieved target retina/choroid concentrations with minimal systemic exposure and demonstrated attractive pharmacokinetic and safety properties and efficacy in destroying abnormal vasculature in a rat choroidal melanoma model. The data were presented at the Glaucoma and Retinopathies 2010 conference by Dai Chaplin, Ph.D., head of research and development and chief scientific officer at OXiGENE.

ZYBRESTAT is being evaluated in a Phase 2 study of patients with non-small cell lung cancer and other clinical trials. OXiGENE believes that ZYBRESTAT is poised to become an important product in a novel class of small-molecule drug candidates called vascular disrupting agents (VDAs). Through interaction with vascular endothelial cell cytoskeletal proteins, ZYBRESTAT selectively targets and collapses tumor vasculature, thereby depriving the tumor of oxygen and causing death of tumor cells. In clinical trials in solid tumors, ZYBRESTAT has demonstrated potent and selective activity against tumor vasculature, as well as clinical activity against ATC, ovarian cancer and various other solid tumors.

The Company’s major focus is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal blood vessels associated with solid tumor progression and visual impairment. OXiGENE is dedicated to leveraging its intellectual property and therapeutic development expertise to bring life-extending and life-enhancing medicines to patients.

**************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

To unsubscribe: unsubscribe@drstockpick.com

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer ) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Crown Equity Holdings Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and received an additional 1,000,000 shares 144 restricted stocks for a continuation of 6 months of advertisement and disseminating news, as well as $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB). Recently, Crown Equity Holdings, Inc has received an additional amount of 2,000,000 shares of free trading stock for 60 days media advertisement, web design and maintenance for Power 3 Medical Products Inc. (PWRM.OB)

Crown Equity Holdings Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB)